Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Long-term Results after 1,144 CarboMedics Mechanical Valve Implantation

CarboMedics 기계판막을 이용한 1,144예 판막치환술의 장기 성적

  • Kang, Chang-Hyun (Dept. of Thoracic and Cardiovascular Surgery, Seoul National University Hospital) ;
  • Kim, Kyung-Hwan (Dept. of Thoracic and Cardiovascular Surgery, Seoul National University Hospital) ;
  • Kim, Ki-Boong (Dept. of Thoracic and Cardiovascular Surgery, Seoul National University Hospital) ;
  • Ahn, Hyuk (Dept. of Thoracic and Cardiovascular Surgery, Seoul National University Hospital)
  • 강창현 (서울대학교 의과대학 흉부외과학교실) ;
  • 김경환 (서울대학교 의과대학 흉부외과학교실) ;
  • 김기봉 (서울대학교 의과대학 흉부외과학교실) ;
  • 안혁 (서울대학교 의과대학 흉부외과학교실)
  • Published : 2004.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

The CarboMedics mechanical valve has been reported to show acceptable valve-related complication rates. The aim of this study is to evaluate our clinical experience with the CarboMedics valve. Material and Method: Between August 1988 and September 1999, we implanted 1,144 CarboMedics valves in 850 patients (aortic 179; mitral 385; double-valve 234; tricuspid 52). The mean age was 44.5 $\pm$ 12.5 years. Follow-up was completed in 95.2% and median follow-up period was 7.9 years (6753 patient-years). Result: The overall hospital mortality rate was 3.4% and the mortality rate for each group was 1.7% for aortic group, 2.6% for mitral group, 4.7% for double-valve group, and 9.6% for tricuspid group, Tricuspid group showed significantly higher mortality rate than aortic and mitral group (p〈0.05). The actuarial survival at 10 years was 87.1 $\pm$ 2.6%, 88.9 $\pm$ 1.7%, 82.4 $\pm$ 2.9%, and 77.5 $\pm$ 7.0% for aortic, mitral, double, and tricuspid valve group, respectively. Age and tricuspid valve replacement were significant risk factors for long-term survival in multivariate analysis (p 〈 0.05). Freedom from valve thrombosis at 10 years was 99.4 $\pm$ 0.6%, 98.2 $\pm$ 0.8%, 99.2 $\pm$ 0.8%, and 87.6 $\pm$ 0.5% for aortic, mitral, double and tricuspid valve group. Tricuspid valve group showed significantly higher rate of valve thrombosis (p 〈 0.05). Conclusion: Long-term results of our experience demonstrated that CarboMedics valve showed acceptable incidence of valve-related complications. However, tricuspid valve replacement showed higher rate of early mortality and valve thrombosis than other valve replacement groups.

CarboMedics 기계판막은 낮은 판막관련 합병증을 보인다고 보고되어 왔다. 이 논문의 목적은 CarboMedics기계판막 치환술 후 장기 임상성적을 분석하고자 하였다. 대상 및 방법: 1988년 8월부터 1999년 9월까지 850명의 환자를 대상으로 1144예의 CarboMedics 판막치환술이 이루어졌다(대동맥판막 치환군 179예, 승모판막 치환군 385예, 이중판막치환군 234예, 삼첨판막 치환군 52예). 환자들의 평균연령은 44.5 $\pm$ 12.5세였고 완전 추적관찰은 95.3%의 환자에서 이루어졌으며, 평균 추적관찰 기간은 7.9년이었다. 결과: 병원 사망률은 3.4%였으며, 환자군에 따라 분류하면 대동백판막군 1.7%, 승모판막군이 2.6%, 이중판막군 4.7%, 그리고 삼첨판막군 9.6%로서 삼첨판막군이 대동맥판막군이나 승모판막군보다 수술사망률이 높았다(p〈0.05). 대동맥판막군, 승모판막군, 이중판막군, 그리고 삼첨판막군의 10년 생존율은 각각 87.1 $\pm$ 2.6%, 88.9 $\pm$ 1.7%, 82.4 $\pm$ 2.9%, 그리고 77.5 $\pm$ 7.0% 였으며, 환자의 연령과 삼첨판막 치환술이 다변량분석에서 장기생존에 영향을 미치는 위험인자였다(p〈0.05). 대동맥판막군, 승모판막군, 이중판막군, 그리고 삼첨판막군의 10년 혈전색전증 회피율은 92.5 $\pm$ 2.3%, 94.2 $\pm$ 1.4%, 94.3 $\pm$ 1.7%, 그리고 97.8 $\pm$ 2.2%였으며, 10년 항응고제 연관 출혈 회피율은 92.5 $\pm$ 2.6%, 93.0 $\pm$ 1.5%, 96.7 $\pm$ 1.3%, 그리고 88.6 $\pm$ 5.5%였으며, 10년 판막혈전증 회피율은 99.4 $\pm$ 0.6%, 98.2 $\pm$ 0.8%, 99.2 $\pm$ 0.8%, 그리고 87.6 $\pm$ 0.5%로서 삼첨판막군이 다른 판막 치환군에 비해 의미 있게 높은 판막혈전증의 발생을 보였다(p 〈0.05). 결론: CarboMedics 기계판막을 이용한 판막치환술의 장기성적에서 만족할 만한 생존율과 낮은 판막관련 합병증을 확인할 수 있었다. 그러나 삼첨판막 치환술은 다른 위치의 판막치환술과 비교하여 높은 수술사망률과 판막혈전증의 빈도를 보였다.

Keywords

References

  1. Korean J Thorac Cardiovasc Surg v.26 Midterm experience with the CarboMedics medical valve Kim,K.C.;Chae,H.;Ahn,H.;Kim,Y.J.;Kim,J.H.;Rho,J.R.
  2. Ann Thorac Surg v.65 The Carbomedics vavle: Experience with 1049 implants Bernal,J.M.;Rabasa,J.M.;Garcia,F.G.;Morales,C.;Nistal,J.F.;Revuelta,J.M. https://doi.org/10.1016/S0003-4975(97)01238-1
  3. Ann Thorac Surg v.73 Up to 8-year follow-up of valve replacement with CarboMedics valve Soga,Y.;Okabaysahi,H.;Nishina,T.(et al.) https://doi.org/10.1016/S0003-4975(01)03424-5
  4. Ann Thorac Surg v.63 Fiver-year follow up after heart valve replacement with the Carbomedics bileaflet prosthesis Rodler,S.M.;Moritz,A.;Schreiner,W.;End,A.;Dubsky,P.;Wolner,E. https://doi.org/10.1016/S0003-4975(97)00174-4
  5. Ann Thorac Surg v.66 Up to eight years' follow up of 997 patients receiving the Carbomedics prosthetic heart valve Fiane,A.E.;Gerian,O.R.;Svenning,J.L. https://doi.org/10.1016/S0003-4975(98)00443-3
  6. Ann Thorac Surg v.69 A Single center experience with 1,378 Carbomedics mechanical valve implants Dalrymple-Hay,M.J.R.;Pearce,R.;Dawkins,S.(et al.) https://doi.org/10.1016/S0003-4975(99)01292-8
  7. J Thorac Cardiovasc Surg v.112 Clinical experience with the Carbomedics valve: Early results with a new bileaflet mechanical prosthesis Nistal,J.F.;Aquilino,H.;Revuelta,J.M.;Gandarillas,M. https://doi.org/10.1016/S0022-5223(96)70178-2
  8. Ann Thorac Surg v.58 Four-year experience with the Carbomedics valve: The North American Experience Copeland,Ⅲ.J.G.;Sethi,G.K. https://doi.org/10.1016/0003-4975(94)90719-6
  9. J Thorac Cardiovasc Surg v.106 Midterm follow up after heart valve replacement with Carbomedics bileaflet prosthesis De Luca,L.;Vitale,N.;Giannolo,B.;Caferella,G.;Piazza,L.;Cotrufo,M.
  10. Eur J Cardiothroac Surg v.15 Carbomedics prosthetic heart vavle Craver,J. https://doi.org/10.1016/S1010-7940(98)00275-9
  11. Korean J Thorac Cardiovasc Surg v.33 Long term results of CarboMedics mechanical valve Kim,B.Y.;Lim,Y.T.;Chung,S.H.;Kang,K.H.;Lee,J.H.
  12. Korean J Thorac Cardiovasc Surg v.33 Ten-year clinical experience with CarboMedics valve Kim,G.G.;Lee,E.B.;Cho,J.Y.(et al.)
  13. Ann Thorac Surg v.52 Comparative study of hemodynamic function of the Carbomedics valve Butterfield,M.;Fisher,J.;Davies,G.A.;Spypt,T.J. https://doi.org/10.1016/0003-4975(91)91217-J
  14. J Thorac Cardiovasc Surg v.123 Prospective randomized comparison of CarboMedics and St Jude Medical bileaflet mechanical heart valve prosthesis: An interim report Lim,K.H.;Caputo,M.;Ascione,R.(et al.) https://doi.org/10.1067/mtc.2002.119703
  15. Ann Thorac Surg v.62 Guidelines for reporting morbidity and mortality after cardiac vavlular operations Edmund,L.H.;Clark,R.E.;Cohn,L.H.;Grunkemeier,G.L.;Miller,C.;Weisel,R.D. https://doi.org/10.1016/S0003-4975(96)00531-0
  16. J Thorac Cardiovasc Surg v.100 Ten year experience with the St. Jude mechanical valve for primary valve replacement Czer,L.S.;Chaux,A.;Matloff,J.M.(et al.)
  17. Ann Thorac Surg v.47 Ten years' experience with the St. Jude Medical valve prosthesis Arom,K.V.;Nicoloff,D.M.;Kersten,T.E.;Northrup,W.F.Ⅲ;Lindsay,W.G.;Emery,R.W. https://doi.org/10.1016/0003-4975(89)90014-3
  18. J Heart Valve Dis v.4 Prosthetic valve thrombosis Horstkotte,D.;Burckhardt,D.
  19. Ann Thorac Surg Outcome analysis of 245 CarboMedics and St. Jude valves implanted at the same institution Rosengart,T.K.;O'Hara,M.;Lang,S.J.(et al.)
  20. J Thorac Cardiovasc Surg v.110 Tricuspid valve replacement: postoperative and long-term results Van Nooten,G.J.;Cases,F.;Taeymans,Y.(et al.) https://doi.org/10.1016/S0022-5223(95)70098-6
  21. Thorax v.39 Thrombotic obstruction of the Bjork-Shiley vavle: The Glasgow experience Ryder,S.I.;Bradley,H.;Vrannan,J.J.;Turner,M.A.;Bain,W.H. https://doi.org/10.1136/thx.39.7.487
  22. Circulation v.78 Low risk of thrombosis and serious embolic events despite low intensity anticoagulation: experience with 1004 Medtronic-Hall valves Butchart,E.G.;Lewis,P.A.;Grunkemeier,G.L.
  23. J Heart Valve Dis v.2 Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude medical prosthesis Horstkotte,D.;Schulte,H.;Bircks,W.;Strauer,B.
  24. Eur J Cardiothorac Surg v.16 Reoperation for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk Rizzoli,G.;Guglielmi,C.;Toscano,G.(et al.) https://doi.org/10.1016/S1010-7940(99)00124-4
  25. Ann Thorac Surg v.66 Tricuspid valve replacement: UK Heart Valve Registry mid-term results comparing mechanical and biological prostheses Ratnatunga,C.P.;Edwards,M.B.;Dore,C.J.;Taylor,K.M. https://doi.org/10.1016/S0003-4975(98)01183-7